OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million
04 oct. 2024 16h57 HE
|
Reneo Pharmaceuticals, Inc.; OnKure Therapeutics, Inc.
OnKure Announces Closing of Merger with Reneo Pharmaceuticals
Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure
02 oct. 2024 20h20 HE
|
Reneo Pharmaceuticals, Inc.
– Combined company to trade on Nasdaq under ticker “OKUR” – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc....
Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results
13 août 2024 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals and OnKure Announce Proposed Merger
13 mai 2024 07h35 HE
|
Reneo Pharmaceuticals, Inc.; OnKure, Inc
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have...
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
07 mai 2024 07h35 HE
|
Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals Reports First Quarter 2024 Financial Results
Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update
28 mars 2024 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for...
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
14 déc. 2023 09h05 HE
|
Reneo Pharmaceuticals, Inc.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE...
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
13 nov. 2023 07h35 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
02 nov. 2023 07h50 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings
25 oct. 2023 07h50 HE
|
Reneo Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...